Business Context and Reporting Period
Company: Glaukos Corporation (GKOS)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2025
Business Overview: Glaukos is an ophthalmic pharmaceutical and medical technology company focused on dropless platform therapies for glaucoma, corneal disorders, and retinal diseases. Key products include the iStent family (MIGS devices), iDose TR (intracameral implant), and Photrexa (keratoconus treatment).
Key Financial Metrics
| Metric (in thousands) | Q2 2025 | Q2 2024 | 6M 2025 | 6M 2024 |
|---|---|---|---|---|
| Net Sales | $124,120 | $95,690 | $230,784 | $181,312 |
| Gross Profit | $97,224 | $73,140 | $179,572 | $138,504 |
| Gross Margin | 78% | 76% | 78% | 76% |
| Operating Expenses | $119,913 | $103,114 | $222,939 | $207,544 |
| Loss from Operations | $(22,689) | $(29,974) | $(43,367) | $(69,040) |
| Net Loss | $(19,657) | $(50,545) | $(37,803) | $(91,383) |
| Diluted Net Loss Per Share | $(0.34) | $(1.00) | $(0.66) | $(1.82) |
Liquidity and Balance Sheet Highlights (as of June 30, 2025)
- Cash and Cash Equivalents: $100.8 million
- Short-term Investments: $174.0 million
- Total Current Assets: $436.1 million
- Total Current Liabilities: $79.1 million
- Working Capital: $356.9 million
- Accumulated Deficit: $(783.2) million
- Debt: No convertible senior notes outstanding (fully redeemed/exchanged in 2024). Finance lease liabilities total $68.8 million.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 30% in Q2 2025 and 27% in the first six months of 2025 compared to the prior year. This was driven primarily by higher volumes of iDose TR sales, partially offset by lower volumes of the iStent family due to Medicare Administrative Contractor (MAC) coverage restrictions on combined MIGS procedures.
- Profitability Improvement: Net loss decreased significantly (61% in Q2, 59% in 6M) compared to the prior year. This improvement is largely attributable to the absence of a $18.0 million non-cash charge associated with the exchange of convertible senior notes in Q2 2024.
- Operating Expenses: SG&A expenses increased 26% in Q2 2025, driven by higher compensation costs (including $5.5 million in incremental stock-based compensation) and expanded commercial infrastructure. R&D expenses increased 6%.
- Acquisitions: In May 2025, the company acquired Mobius Therapeutics for $12.4 million (net of cash) plus contingent consideration, adding the Mitosol product to its portfolio.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- iDose TR: Management anticipates increased utilization as reimbursement processes become more consistent across MACs. A supplemental NDA for re-administration has a PDUFA date in January 2026.
- Corneal Health: The company expects potential disruption in the U.S. Corneal Health franchise as the market transitions from Photrexa to Epioxa (PDUFA date: October 20, 2025), a surgery-free topical therapy.
- International Expansion: Received EU MDR certification for the iStent family in June 2025; commercial launch in key EU markets is expected in the second half of 2025.
- Capital Expenditures: Construction on a new 200,000 sq. ft. R&D and manufacturing facility in Huntsville, Alabama, is expected to begin in 2026.
Key Risks and Contingencies
- Reimbursement Uncertainty: Finalized Local Coverage Determinations (LCDs) by five MACs restrict combined MIGS procedures, impacting iStent volumes. Physician fee rates for iDose TR are still being finalized by MACs.
- Commercial Success of iDose TR: Success depends on physician adoption, manufacturing capacity, and consistent reimbursement.
- Supply Chain: Reliance on limited third-party suppliers for components; potential disruptions could impact gross margins and delivery.
- Regulatory: Risks associated with FDA approvals for pipeline products (e.g., Epioxa) and compliance with EU MDR/UK MDR regulations.
Investor Verification Checklist
- Reimbursement Status: Verify the finalization of physician fee payment rates for iDose TR by the remaining Medicare Administrative Contractors (MACs).
- iStent Volume Trends: Monitor the extent to which MAC restrictions on combined MIGS procedures continue to suppress iStent family sales volumes.
- Acquisition Integration: Assess the commercial integration and initial sales performance of the newly acquired Mobius Therapeutics (Mitosol).
- Regulatory Milestones: Track the FDA decision date for Epioxa (October 20, 2025) and the potential impact on the Photrexa franchise.
- Cash Burn Rate: Review the trajectory of operating cash burn given the continued net losses and significant R&D/SG&A investments.